Integra LifeSciences (NASDAQ:IART) Shares Up 8.3% After Insider Buying Activity

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) rose 8.3% during mid-day trading on Friday following insider buying activity. The company traded as high as $12.13 and last traded at $12.15. Approximately 265,588 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 1,068,571 shares. The stock had previously closed at $11.22.

Specifically, Director Jeffrey A. Graves bought 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The stock was purchased at an average price of $11.35 per share, for a total transaction of $102,150.00. Following the completion of the transaction, the director owned 41,086 shares in the company, valued at $466,326.10. The trade was a 28.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Analysts Set New Price Targets

Several research analysts have commented on IART shares. Citigroup dropped their price objective on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a report on Friday, October 31st. JPMorgan Chase & Co. lifted their price objective on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Truist Financial reiterated a “hold” rating and set a $13.00 target price (down from $15.00) on shares of Integra LifeSciences in a report on Monday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Integra LifeSciences in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $15.83.

Integra LifeSciences Stock Up 6.6%

The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23. The business’s 50 day moving average price is $14.44 and its 200 day moving average price is $13.70. The firm has a market cap of $931.59 million, a price-to-earnings ratio of -1.82 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.11. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company had revenue of $402.06 million during the quarter, compared to analysts’ expectations of $414.31 million. During the same period in the prior year, the business posted $0.41 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. On average, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of Integra LifeSciences by 55.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 913 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in shares of Integra LifeSciences by 205.9% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after acquiring an additional 2,108 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the last quarter. AlphaQuest LLC purchased a new stake in shares of Integra LifeSciences in the 2nd quarter valued at approximately $73,000. Finally, EMC Capital Management purchased a new stake in shares of Integra LifeSciences during the 2nd quarter worth $75,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.